Ardijana Novaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ardijana Novaj has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ana Leda Figueiredo Longhini
Flow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
3 shared publications - Anne Roulston
Repare Therapeutics, Saint-Laurent, Canada
3 shared publications - Atif J. Khan
Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications - Diana Mandelker
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, NY
3 shared publications - Ezra Rosen
Memorial Sloan Kettering Cancer Center 5 Evelyn H. Lauder Breast Center New York, New York
3 shared publications - Fresia Pareja
Memorial Sloan Kettering Cancer Center
3 shared publications
Latest Publications
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose:The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase.Experimental Design:We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings.Results:Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients.Conclusions:Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments.See related commentary by Schrank and Colbert, p. 5505
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose:The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase.Experimental Design:We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings.Results:Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients.Conclusions:Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments.See related commentary by Schrank and Colbert, p. 5505
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1 from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1 from Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (24) , 5643-5656
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose: The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase. Experimental Design: We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings. Results: Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients. Conclusions: Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments. See related commentary by Schrank and Colbert, p. 5505
- 9 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (24) , 5643-5656
Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy
Purpose: The importance of the DNA damage response in mediating effects of radiotherapy (RT) has galvanized efforts to target this pathway with radiosensitizers. Yet early clinical trials of this approach have failed to yield a benefit in unselected populations. We hypothesized that ataxia–telangiectasia mutated (Atm)–null tumors would demonstrate genotype-specific synergy between RT and an inhibitor of the DNA damage response protein ataxia–telangiectasia and Rad3-related (ATR) kinase. Experimental Design: We investigated the synergistic potential of the ATR inhibitor (ATRi) RP-3500 and RT in two Atm-null and isogenic murine models, both in vitro and in vivo. Staining of γ-H2AX foci, characterization of the immune response via flow cytometry, and tumor rechallenge experiments were performed to elucidate the mechanism of interaction. To examine genotype specificity, we tested the interaction of ATRi and RT in a Brca1-null model. Finally, patients with advanced cancer with ATM alterations were enrolled in a phase I/II clinical trial to validate preclinical findings. Results: Synergy between RP-3500 and RT was confirmed in Atm-null lines in vitro, characterized by an accumulation of DNA double-strand breaks. In vivo, Atm-null tumor models had higher rates of durable control with RT and ATRi than controls. In contrast, there was no synergy in tumors lacking Brca1. Analysis of the immunologic response indicated that efficacy is largely mediated by cell-intrinsic mechanisms. Lastly, early results from our clinical trial showed complete responses in patients. Conclusions: Genotype-directed radiosensitization with ATRi and RT can unleash significant therapeutic benefit and could represent a novel approach to develop more effective combinatorial synthetic cytotoxic RT-based treatments. See related commentary by Schrank and Colbert, p. 5505